Terms: = Prostate cancer AND EXT1, ttv, 2131, ENSG00000182197, EXT, Q16394 AND Treatment
13 results:
1. Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic prostate cancer.
de Jong AC; Isebia KT; Ling SW; de Weerd V; Van NM; Kraan J; Martens JWM; Mehra N; Hamberg P; Lolkema MP; de Wit R; van der Veldt AAM; Wilting SM
JCO Precis Oncol; 2023 Sep; 7():e2300156. PubMed ID: 38061007
[TBL] [Abstract] [Full Text] [Related]
2.
de Jong AC; Segbers M; Ling SW; Graven LH; Mehra N; Hamberg P; Brabander T; de Wit R; van der Veldt AAM
J Nucl Med; 2023 Oct; 64(10):1556-1562. PubMed ID: 37536738
[TBL] [Abstract] [Full Text] [Related]
3. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant prostate cancer.
Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Calais J; Rettig M; Eiber M; Weber M; Benz MR; Farolfi A
Radiology; 2023 Jul; 308(1):e222148. PubMed ID: 37432081
[TBL] [Abstract] [Full Text] [Related]
4.
John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Mar; 64(3):410-415. PubMed ID: 36215568
[No Abstract] [Full Text] [Related]
5. Evaluation of
Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120
[No Abstract] [Full Text] [Related]
6. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
7. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Thiery-Vuillemin A; Fizazi K; Sartor O; Oudard S; Bury D; Thangavelu K; Ozatilgan A; Poole EM; Eisenberger M; de Bono J
ESMO Open; 2021 Apr; 6(2):100089. PubMed ID: 33740734
[TBL] [Abstract] [Full Text] [Related]
8. Molecular analysis of circulating tumor cells of metastatic castration-resistant prostate cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
9. Repeatability of Quantitative
Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
[TBL] [Abstract] [Full Text] [Related]
10. Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy.
Filss C; Heinzel A; Miiller B; Vogg ATJ; Langen KJ; Mottaghy FM
Nuklearmedizin; 2018 Feb; 57(1):19-25. PubMed ID: 29536496
[TBL] [Abstract] [Full Text] [Related]
11. A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.
Korzeniowski MA; Crook JM; Bowes D; Gaztañaga M; Ots A; Jazwal J; Rose J; Tétreault-Laflamme A; Pilote L; Halperin R; Kim D; Petrik D; Araujo C; Bachand F
Brachytherapy; 2018; 17(3):530-536. PubMed ID: 29398594
[TBL] [Abstract] [Full Text] [Related]
12. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Bassett WW; Cooperberg MR; Sadetsky N; Silva S; DuChane J; Pasta DJ; Chan JM; Anast JW; Carroll PR; Kane CJ
Urology; 2005 Nov; 66(5):1060-5. PubMed ID: 16286124
[TBL] [Abstract] [Full Text] [Related]
13. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract] [Full Text] [Related]
